Abemaciclib mesylate (LY2835219)

For research use only. Not for use in humans.

目录号:S7158 中文名称:甲磺酸阿贝西尼

Abemaciclib mesylate (LY2835219) Chemical Structure

CAS No. 1231930-82-7

Abemaciclib (LY2835219)是一种有效的,选择性CDK4CDK6抑制剂,无细胞试验中IC50分别为2 nM和10 nM。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 4644.52 现货
RMB 2203.44 现货
RMB 3333.88 现货
RMB 6544.35 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Abemaciclib mesylate (LY2835219)发表文献48篇:

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述 Abemaciclib (LY2835219)是一种有效的,选择性CDK4CDK6抑制剂,无细胞试验中IC50分别为2 nM和10 nM。Phase 3。
靶点
CDK4 [1]
(Cell-free assay)
CDK6 [1]
(Cell-free assay)
2 nM 10 nM
体外研究

LY2835219是一种口服有效的细胞周期蛋白依赖性激酶(CDK)抑制剂,靶向作用于CDK4(cyclin D1)和CDK6(cyclin D3)细胞周期通路,具有潜在的抗肿瘤活性。LY2835219特异性抑制CDK4和6,从而在早G1期抑制视网膜母细胞瘤(Rb)蛋白磷酸化。抑制Rb磷酸化,防止CDK-介导的G1-S期转换,从而使细胞周期停滞在G1期,抑制DNA合成,且抑制癌细胞生长。某些类型的癌症中丝/苏氨酸激酶CDK4/6的过表达,导致细胞周期调节失控。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human COLO205 cells MXzGeY5kfGmxbjDhd5NigQ>? NV3i[FZqOjRiaB?= MYrJcohq[mm2aX;uJI9nKEOGS{SvOkBqdiCqdX3hckBEV0yRMkC1JINmdGy|IHHzd4V{e2WmIHHzJI1igGmvdX2gZ4VtdCCleXPs[UBienKnc4SgZZQhTzFicHjhd4Uh[W[2ZYKgNlQhcHK|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{ MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNUW3NUc,OjZzMUW1O|E9N2F-
human COLO205 cells NGewfGpHfW6ldHnvckBie3OjeR?= NFL4RVEzPCCq NH3VN4FKdmirYnn0bY9vKG:oIFPET|QwPiCrbjDoeY1idiCFT1zPNlA2KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gVoIheGixc4Doc5J6dGG2aX;uJIFnfGW{IEK0JIhzeyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKGyjc3XyMZNk[W6waX7nJIZtfW:{ZYPj[Y5k\SCvaXPyc5Bt[XSnIHP5eI9u\XS{aXOgZY5idHm|aYO= NYHjT2xSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVU2PzFpPkK2NVE2PTdzPD;hQi=>
insect cells  MYHGeY5kfGmxbjDhd5NigQ>? MnixOVAhdWmwcx?= NV\DVIQyUW6qaXLpeIlwdiCxZjDoeY1idiCFRFu0M4N6[2yrbjDENUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbI9zgWyjdHnvckBw\iCFVGLGJIFnfGW{IEWwJI1qdnNiYomgcYlkem:ybHH0[UB{[2mwdHnscIF1cW:wIHPveY51\XJuIFnDOVA:OiCwTR?= NF3NT|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxOVU4OSd-Mk[xNVU2PzF:L3G+
insect cells  NWjOfGJwTnWwY4Tpc44h[XO|YYm= NH60T|c2OCCvaX7z M{H0RmNwdXCndHn0bZZmKGmwaHnibZRqd25ib3[gbJVu[W5iQ1TLOE9kgWOuaX6gSFEh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTpc44hd2ZiQ2TSSkBi\nSncjC1NEBucW6|IHL5JG1q[2ijZXzpd{1O\W62ZX6gdIxwfCCjbnHsfZNqeyCrbjDwdoV{\W6lZTDv[kBCXFBuIFvpQVAvPiCwTR?= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNUW3NUc,OjZzMUW1O|E9N2F-
HCT116 M3Ox[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NVvXbnZwPzJiaILz NV:3bG1FUUN3MDC9JFAvPTRizszN MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF4NUO0NUc,OzBzNkWzOFE9N2F-
MCF7 MXjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NWewXZk3PzJiaILz NH3JeFhKSzVyIE2gNE44OSEQvF2= M121[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMU[1N|QyLz5|MEG2OVM1OTxxYU6=
PANC1 M2D0NGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MmTRO|IhcHK| MVXJR|UxKD1iNT65OEDPxE1? NWPqW|ZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxOlU{PDFpPkOwNVY2OzRzPD;hQi=>
Sf9 NEnvfXdHfW6ldHnvckBie3OjeR?= MVzJcohq[mm2aX;uJI9nKEOGS{GvR5lkdGmwIFKgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4h[mGldXzveolz[WxiaX7m[YN1\WRiaX7z[YN1KFOoOTDj[YxteyC3c3nu[{BpcXO2b37lJGgyKGG|IIP1ZpN1emG2ZTDpckBxemW|ZX7j[UBw\iCdZ3HtcYEuOzOSXVHUVEwhUUN3MDC9JFAvOzdzIN88UU4> M1Ha[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{SxPFU{Lz5{Nke0NVg2OzxxYU6=
Sf9 M4K3SmZ2dmO2aX;uJIF{e2G7 M4L2dVkxKG2rboO= NY\pcoc5UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhS0SNNDCoOEB1dyB|MEOgdoV{cWS3ZYOpM4N6[2yrbjDENUApPCC2bzCyPVUhemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDz[lkh[2WubIOgeZNqdmdiQz30[ZJucW6jbDDy[ZRqdm:kbHHzeI9u[SCocnHncYVvfCCjczDzeYJ{fHKjdHWgZYZ1\XJiOUCgcYlveyCkeTDb[4FudWFvM{PQYWFVWCCkYYPl[EBucWO{b3LleIEhe2OrboTpcIxifGmxbjDjc5VvfGmwLDDLbUA:KDBwMECyJO69VS5? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
Sf9 NIXnWYtHfW6ldHnvckBie3OjeR?= MmPJPVAhdWmwcx?= NYD5UYF4UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBnfWyuIHzlcod1cCCqdX3hckBPNXSncn3pcoFtKEeVVD30ZYdo\WRiQ1TLOkApOSC2bzCzNlYhemW|aXT1[ZMqN2O7Y3zpckBFOSBqNDD0c{AzQTVicnXzbYR2\XNrIHX4dJJme3OnZDDpckB{\jliY3XscJMhfXOrbnegR{11\XKvaX7hcEBz\XSrbn;icIF{fG:vYTDmdoFodWWwdDDhd{B{fWK|dILheIUh[W[2ZYKgPVAhdWmwczDifUBc\2GvbXGtN|NRZUGWUDDiZZNm\CCvaXPyc4JmfGFic3PpcpRqdGyjLDDLbUA:KDBwMEGg{txONg>? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
Sf21 M{\INGZ2dmO2aX;uJIF{e2G7 NWrmT2lsUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBENXSncn3pcoFtKEirc{[teIFo\2WmIFPET|cw[3mlbHnuJGgwVi22ZYLtbY5idCCJU2SteIFo\2WmIF3BWFEh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnOjFiaX7z[YN1KGOnbHzzJJV{cW6pIHPkb|che3Wkc4TyZZRmKHCncITp[IUtKEurIE2gN{46OSEQvF2u MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN|Y9N2F-
COLO205 M2C4TmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NX3ae3U4QTZiaILz NHjjc3JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPPUG8zODViY3XscJMh[W[2ZYKgPVYhcHK|IHL5JGNEUy16IHHzd4F6NCCLQ{WwJF0hOC52NjFOwG0v NGnRO|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUC3OFI2PCd-MkmwO|QzPTR:L3G+
U87MG NX\3RXI3SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M2X3cVczKGi{cx?= MnHwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCXOEfNS{Bk\WyuczDh[pRmeiB5MjDodpMh[nliRFHQTUB{fGGrbnnu[{Bj[XOnZDDhd5NigSxiSVO1NEA:KDBwMES4NUDPxE1w MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ2N{i1O{c,Ojl{NEe4OVc9N2F-
Sf9 NXrJcWxsTnWwY4Tpc44h[XO|YYm= MXrJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDDSGs1KCiVNDD0c{BGOzB|IILld4llfWW|KT;DfYNtcW5iREGgLHE1KHSxIFmyPVUhemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDz[lkh[2WubIOgeZNqdmdiUnKgdJJwfGWrbjCoO|c{KHSxIEmyPEBz\XOrZIXld{kh[XNic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKFt|M2DdMWFVWCCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKG2ndHjv[EwhUUN3MDC9JFAvODB{IN88UU4> M4ixN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEK5PFMzLz5{OUSyPVg{OjxxYU6=
Sf9 M1;UUmZ2dmO2aX;uJIF{e2G7 MU[5NEBucW6| M4\QSGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR2RMPiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{B2e2mwZzDobZN1d26nIFixJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JGFFWC2JbH:gZZN{[XluIFnDOVAhRSByLkCwO|gh|ryPLh?= M1LEeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEK5PFMzLz5{OUSyPVg{OjxxYU6=
Sf9 M4X2SWZ2dmO2aX;uJIF{e2G7 NXjsT4dIUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhS0SNNDCoUVEhfG9iQUOyOkBz\XOrZIXld{kwS3mlbHnuJGQyKCiTNDD0c{BKOjl3IILld4llfWW|KTDlfJBz\XO|ZXSgbY4he2Z7IHPlcIx{KHW|aX7nJHJjKHC{b4TlbY4hMDd5MzD0c{A6OjhicnXzbYR2\XNrIHHzJJN2[nO2cnH0[UBqdiCycnXz[Y5k\SCxZjDbN|NRZS2DVGCgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDt[ZRpd2RuIFnDOVAhRSByLkCxJO69VS5? NXj6VZE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0Nlk5OzJpPkK5OFI6QDN{PD;hQi=>
Sf9 NV7GU45kTnWwY4Tpc44h[XO|YYm= NHqw[JM6OCCvaX7z MXHJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIFPET|EwS3mlbHnuJGQ{KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIHjpd5RwdmViSEGgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgRWRRNUeubzDhd5NigSxiSVO1NEA:KDBwMEW2JO69VS5? M1fTbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEK5PFMzLz5{OUSyPVg{OjxxYU6=
MDA-MB-231 MnHsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idg>? MX[3NkBpenN? MofmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFczKGi{czDifUBFSVCLIIP0ZYlvcW6pIHLhd4VlKGG|c3H5MEBKSzVyIE2gNE4yQTFizszNMi=> NGXK[ZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSyPVg{Oid-Mkm0Nlk5OzJ:L3G+
COLO205 NYjmOHJpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbh?= M3\heFk3KGi{cx?= MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEORTF:yNFUh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IFPDT|gh[XO|YYmsJGlEPTBiPTCwMlIyPyEQvF2u M4WyclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW5Nlc1Lz5{OUS1PVI4PDxxYU6=
MDA-MB-468 NWTPZXdmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbh?= MkS3PVYhcHK| MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk01PjhiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUA1NjhyODFOwG0v M{XBcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW5Nlc1Lz5{OUS1PVI4PDxxYU6=
COLO205 NHjUOm1KdmirYnn0bY9vKG:oIFPET|QhcW5iaIXtZY4> M2rmPFAvOSC2bzCxNEB2VQ>? M4iyblI1KGi{cx?= MnTSTY5pcWKrdHnvckBw\iCFRFu0JIlvKGi3bXHuJGNQVE9{MEWgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKHSxdHHsJHJjKHC{b4TlbY4hdGW4ZXygZZQhOC5zIITvJFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2dHnu[{Bu\XSqb3S= NVPEZo9ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVkzPzRpPkK5OFU6Ojd2PD;hQi=>
COLO205 M2rkcmNmdGxiY4njcIUh[XO|YYm= Mn;BeZAhfG9iMUCgeW0> NU\k[HpmOjRiaILz NX3qUodlS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hS0:OT{KwOUBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|IwVSCyaHHz[UB2eCC2bzCxNEB2VSCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDGRWNUKGGwYXz5d4l{ MmDLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUmyO|QoRjJ7NEW5Nlc1RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Rb(S780) / Rb / p21; 

PubMed: 26909611     


Effects of LY2835219 on RB phosphorylation and p21 expression were evaluated by immunoblotting at indicated concentrations (A)

p-ERK / ERK / p-Akt / Akt / p-mTOR(S2448) / mTOR; 

PubMed: 26909611     


Effects of LY2835219 on RB phosphorylation and p21 expression were evaluated by immunoblotting at indicated time points (B).

pRb(S795) / E2F1 / Cyclin A2 / Cyclin E2; 

PubMed: 27748766     


(c) MCF-7 and MR cells were treated with 100 nm LY2835219 and collected at indicated times. Immunoblots were performed with the indicated antibodies. (d) MCF-7 and MR cells were treated with increasing concentrations of LY2835219 and harvested after 24 h; lysates were then subjected to immunoblotting.

26909611 27748766
Growth inhibition assay
Cell viability; 

PubMed: 26909611     


Cell viability of OSC-19, FaDu, and YD-10B cells treated with LY2835219 at indicated concentrations. Data are representative of three independent experiments: mean ± SEM.

26909611
体内研究 LY2835219-MsOH处理脑的剂量百分比为0.5–3.9%。LY2835219-MsOH处理皮下和颅内胶质瘤模型(U87MG),抑制肿瘤生长,这种作用存在剂量依赖性,不管是单独处理,还是与Temozolomide联用。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 Water 100 mg/mL (165.92 mM)
DMSO 83 mg/mL (137.71 mM)
Ethanol '''24 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water
100mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 602.7
化学式

C27H32F2N8.CH4O3S

CAS号 1231930-82-7
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04752332 Not yet recruiting Drug: Abemaciclib|Drug: Standard Adjuvant ET|Drug: Placebo Breast Neoplasms Eli Lilly and Company May 12 2021 Phase 3
NCT04408924 Recruiting Drug: Abemaciclib Metastatic Castration-Resistant Prostate Cancer Eli Lilly and Company January 20 2021 Phase 2
NCT04238819 Recruiting Drug: Abemaciclib|Drug: Irinotecan|Drug: Temozolomide Relapsed Solid Tumor|Refractory Solid Tumor Eli Lilly and Company November 9 2020 Phase 1
NCT03703466 Active not recruiting Drug: Abemaciclib Metastatic Breast Cancer Eli Lilly and Company November 28 2018 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is your product S7158 LY2835219 “mesylate salt form”?

  • 回答:

    Our S7158 LY2835219 is mesylate salt form.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

相关CDK产品

Tags: 购买Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)供应商 | 采购Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)价格 | Abemaciclib mesylate (LY2835219)生产 | 订购Abemaciclib mesylate (LY2835219) | Abemaciclib mesylate (LY2835219)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID